Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2023-02-07 Director's Dealing
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-02-07 English
SC 13G/A
Major Shareholding Notification
2023-02-03 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 2, 2023. It primarily announces amendments to the company's bylaws, including changes related to proxy rules and stockholder meeting procedures. There are no financial statements or detailed financial data included. The focus is on governance changes approved by the board of directors. This fits the category of Board/Management Information (MANG), as it relates to changes in corporate governance documents and board-approved amendments. The document length is sufficient and contains substantive content about governance changes, not just a brief announcement or certification. Therefore, the appropriate classification is MANG.
2023-02-03 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-03 English
COWEN FINANCIAL PRODUCTS LLC
Major Shareholding Notification
2023-01-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate updates. The text indicates that the company, Stoke Therapeutics, is furnishing a corporate presentation (Exhibit 99.1) related to a business update and upcoming milestones, specifically for a healthcare conference. The document explicitly states it is a Current Report on Form 8-K and includes forward-looking statements and business updates but does not contain comprehensive financial statements or detailed financial analysis. The nature of the content is an update on corporate events and presentation materials rather than a full financial report or earnings release. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings like Form 8-K that do not fit other specific categories.
2023-01-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.